The departure of Joseph Bolen from Moderna Therapeutics as its CSO last year, as well as other subsequent high-profile exoduses, has caused much speculation about the health of this ambitious biotech unicorn.
Now, Bolen is back as the CSO of PureTech Health, a venture firm that has since morphed a bit over the years into a publicly listed therapeutic discovery and development company.
There, he will lead the work on PureTech’s pipeline, which focuses on immune, nervous and gastrointestinal systems and includes more than 20 ongoing clinical trials. PureTech has 5 candidates that are in proof-of-concept studies, as well as multiple pivotal data readouts in the next couple of years.
“PureTech Health is one of the most exciting companies in biotech, advancing truly unique multi-modal solutions to some of today’s most significant healthcare challenges through modulation of the human nervous and immune adaptive systems,” Bolen said in a statement. “Our mission at PureTech Health is to collaborate broadly with biomedical science and technology leaders in order to generate the most exciting ideas and then to transform these concepts into breakthrough medicines.”
In this new role, Dr. Bolen will lead the scientific development and advancement of PureTech’s pipeline and will work closely with the team and Scientific Advisory Board as the company identifies and pursues new modalities to address significant medical needs.
Bolen held the position of CSO with Moderna for only 10 months, departing in October 2015. He started out at the Cambridge, MA-based company as its president of R&D; he held that spot for a little over a year and a half. Prior to that, he had been the CSO at Millennium Pharmaceuticals for 14 years. Millennium was acquired by Takeda in 2008 for $8.8 billion.
“Joe is a seasoned industry expert who brings the ideal balance of rigor and creativity to the role of CSO, and shares our vision for identifying and nurturing innovation that can potentially redefine healthcare,” said PureTech CEO Daphne Zohar.
By Stacy Lawrence
Source: Fierce Biotech
CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.
FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.
